These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 5451221)

  • 41. Studies with ifosfamide in patients with malignant lymphoma.
    Rodriguez V; Cabanillas F; Bodey GP; Freireich EJ
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):87-92. PubMed ID: 7163815
    [No Abstract]   [Full Text] [Related]  

  • 42. Toxicity of E. coli L-asparaginase in man.
    Oettgen HF; Stephenson PA; Schwartz MK; Leeper RD; Tallai L; Tan CC; Clarkson BD; Golbey RB; Krakoff IH; Karnofsky DA; Murphy ML; Burchenal JH
    Cancer; 1970 Feb; 25(2):253-78. PubMed ID: 4905153
    [No Abstract]   [Full Text] [Related]  

  • 43. Cyclophosphamide regimens in rhesus monkey with and without marrow infusion.
    Storb R; Buckner CD; Dillingham LA; Thomas ED
    Cancer Res; 1970 Aug; 30(8):2195-203. PubMed ID: 4990004
    [No Abstract]   [Full Text] [Related]  

  • 44. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Leukotoxic effect of homologous human antileukocyte plasma (HALP)].
    Thierfelder S; Pfisterer H; Tsirimbas A; Mempel W; Hornung B; Eulitz M; Stich W
    Klin Wochenschr; 1969 Apr; 47(7):366-71. PubMed ID: 5383390
    [No Abstract]   [Full Text] [Related]  

  • 46. Burkitt's tumor in the United States.
    Cohen MH; Bennett JM; Berard CW; Ziegler JL; Vogel CL; Sheagren JN; Carbone PP
    Cancer; 1969 Jun; 23(6):1259-72. PubMed ID: 5771062
    [No Abstract]   [Full Text] [Related]  

  • 47. Immunologic studies in American patients with Burkitt-like lymphoma.
    Ziegler JL; Cohen MH; Vogel CL; Sheagren JN; Carbone PP
    Cancer Res; 1967 Dec; 27(12):2527-31. PubMed ID: 4170383
    [No Abstract]   [Full Text] [Related]  

  • 48. High-dose daunorubicin therapy for acute nonlymphocytic leukemia: correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity.
    Greene W; Huffman D; Wiernik PH; Schimpff S; Benjamin R; Bachur N
    Cancer; 1972 Dec; 30(6):1419-27. PubMed ID: 4264560
    [No Abstract]   [Full Text] [Related]  

  • 49. Results of treatment of Burkitt's lymphoma patients in the West Nile District of Uganda at Kuluva Hospital.
    Williams EH; Breslow NE; Edlestein R
    East Afr Med J; 1982 Dec; 59(12):785-92. PubMed ID: 7184758
    [No Abstract]   [Full Text] [Related]  

  • 50. [A therapeutic approach in Burkitt's lymphoma. 2 case reports from the Hospital Central da Beira/Mozambique].
    Schneidewind A
    Fortschr Med Orig; 2001; 119(1):5-8. PubMed ID: 11935660
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chemotherapy in Burkitt's Tumour.
    Pike MC
    Lancet; 1966 Oct; 2(7468):856. PubMed ID: 4162182
    [No Abstract]   [Full Text] [Related]  

  • 52. Short-term sequential therapy with vinblastine (NSC-49842) and cyclophosphamide (NSC-26271) in Hodgkin's disease.
    DeConti RC; Mitchell MS; Marsh JC; Bertino JR
    Cancer Chemother Rep; 1971 Dec; 55(5):607-10. PubMed ID: 4946083
    [No Abstract]   [Full Text] [Related]  

  • 53. Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas.
    Mathé G; Schwarzenberg L; Pouillart P; Oldham R; Weiner R; Jasmin C; Rosenfeld C; Hayat M; Misset JL; Musset M; Schneider M; Amiel JL; De Vassal F
    Cancer; 1974 Oct; 34(4):985-92. PubMed ID: 4608026
    [No Abstract]   [Full Text] [Related]  

  • 54. [Hiccups ad severe hyponatremia induced by low dose cyclophosphamide therapy for Burkitt lymphoma].
    Tazi I; Zaoui S; Nafil H; Mahmal L
    Ann Biol Clin (Paris); 2011; 69(5):613-4. PubMed ID: 22034668
    [No Abstract]   [Full Text] [Related]  

  • 55. The variability of individual tolerance to methotrexate in cancer patients.
    Hansen HH; Selawry OS; Holland JF; McCall CB
    Br J Cancer; 1971 Jun; 25(2):298-305. PubMed ID: 4256007
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The 2000 Burkitt lymphoma trial in Malawi.
    Hesseling P; Broadhead R; Mansvelt E; Louw M; Wessels G; Borgstein E; Schneider J; Molyneux E
    Pediatr Blood Cancer; 2005 Mar; 44(3):245-50. PubMed ID: 15547922
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Ambulatory chemotherapy of hematosarcoma].
    Finogenova IA; Abdylbaev RA
    Vopr Onkol; 1984; 30(3):77-81. PubMed ID: 6369777
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Phase II study of etoposide (NK 171) in advanced hematological malignancies].
    Yoshida T; Nakanishi J; Ito K; Kobayashi S; Ohtake S; Nakamura S; Hattori K
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1579-84. PubMed ID: 6476835
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical trial of the effect of S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide.
    Woolley PV; Ayoob MJ; Smith FP; Dritschilo A
    J Clin Oncol; 1983 Mar; 1(3):198-203. PubMed ID: 6321681
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.
    Moertel CG; Schutt AJ; Reitemeier RJ; Hahn RG
    Cancer Chemother Rep; 1972 Feb; 56(1):95-101. PubMed ID: 5030811
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.